Koxituf 90mg Tablet contains Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor used primarily for the management of pain and inflammation associated with various musculoskeletal and inflammatory conditions. It is indicated for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis. By selectively inhibiting the COX-2 enzyme, Etoricoxib reduces the synthesis of prostaglandins responsible for inflammation, pain, and fever, while sparing COX-1, thereby minimizing gastrointestinal adverse effects commonly associated with non-selective nonsteroidal anti-inflammatory drugs (NSAIDs). Koxituf 90mg is typically administered orally once daily, with dosage adjustments based on clinical response and patient tolerance. It is contraindicated in patients with known hypersensitivity to Etoricoxib or other NSAIDs, active peptic ulcer disease, severe hepatic or renal impairment, and in those with established cardiovascular disease due to potential increased risk of thrombotic events. Caution is advised in patients with hypertension, heart failure, or fluid retention. Common side effects include headache, dizziness, gastrointestinal discomfort, and elevated liver enzymes. Regular monitoring of renal and hepatic function is recommended during prolonged therapy. Koxituf 90mg should be used under medical supervision to ensure safe and effective management of inflammatory conditions.